Azitra, Inc. Announces Q2 2025 Results and Provides Business Updates
Azitra (NYSE American: AZTR), a clinical-stage biopharmaceutical company, reported Q2 2025 financial results and business updates. The company achieved 50% enrollment in Phase 1b trial of ATR-12 for Netherton syndrome, showing promising safety data in the first five patients. Additionally, Azitra secured a $20 million equity line of credit from Alumni Capital LP.
The company's pipeline includes ATR-04, targeting EGFRi-associated rash affecting approximately 150,000 US patients annually. Key upcoming milestones include first patient dosing in ATR-04's Phase 1/2 trial in Q3 2025 and ATR-12's Phase 1b topline data in Q1 2026. Financial results show R&D expenses of $1.4 million, G&A expenses of $1.5 million, and a net loss of $2.9 million, with cash position at $1.0 million.
Azitra (NYSE American: AZTR), azienda biofarmaceutica in fase clinica, ha reso noti i risultati finanziari del Q2 2025 e aggiornamenti aziendali. La societ脿 ha raggiunto il 50% di arruolamento nello studio di Fase 1b di ATR-12 per la sindrome di Netherton, mostrando dati di sicurezza promettenti nei primi cinque pazienti. Inoltre, Azitra ha ottenuto una linea di credito azionaria da $20 million da Alumni Capital LP.
La pipeline include ATR-04, che mira all'eruzione cutanea associata agli inibitori di EGFR e interessa circa 150,000 pazienti negli USA ogni anno. Tra i prossimi traguardi figurano la prima somministrazione al paziente nello studio di Fase 1/2 di ATR-04 nel Q3 2025 e i dati topline della Fase 1b di ATR-12 nel Q1 2026. I risultati finanziari mostrano costi di R&S per $1.4 million, spese G&A per $1.5 million e una perdita netta di $2.9 million, con una posizione di cassa di $1.0 million.
Azitra (NYSE American: AZTR), compa帽铆a biofarmac茅utica en fase cl铆nica, inform贸 resultados financieros del 2T 2025 y novedades corporativas. La empresa logr贸 el 50% de inscripci贸n en el ensayo de Fase 1b de ATR-12 para el s铆ndrome de Netherton, mostrando datos de seguridad prometedores en los primeros cinco pacientes. Adem谩s, Azitra asegur贸 una l铆nea de cr茅dito accionaria de $20 million con Alumni Capital LP.
La cartera incluye ATR-04, orientada a la erupci贸n asociada a inhibidores de EGFR, que afecta aproximadamente a 150,000 pacientes en EE. UU. cada a帽o. Pr贸ximos hitos: dosificaci贸n del primer paciente en el ensayo de Fase 1/2 de ATR-04 en el 3T 2025 y datos topline de la Fase 1b de ATR-12 en el 1T 2026. Las finanzas muestran gastos de I+D por $1.4 million, gastos G&A por $1.5 million y una p茅rdida neta de $2.9 million, con efectivo disponible de $1.0 million.
Azitra (NYSE American: AZTR)電� 鞛勳儊 雼硠鞚� 氚旍澊鞓れ牅鞎� 旮办梾鞙茧 2025雲� 2攵勱赴 鞛 鞁れ爜 氚� 靷梾 鞐呺嵃鞚错姼毳� 氤搓碃頄堨姷雼堧嫟. 須岇偓電� Netherton 歃濏泟甑� 雽�靸� ATR-12鞚� Phase 1b 鞛勳儊鞐愳劀 50% 霌彪鞚� 雼劚頄堨溂氅�, 觳橃潓 雼れ劘 頇橃瀽鞐愳劀 鞙犽頃� 鞎堨爠靹� 雿办澊韯半ゼ 頇曥澑頄堨姷雼堧嫟. 霕愴暅 Azitra電� Alumni Capital LP搿滊秬韯� $20 million 攴滊鞚� 欤检嫕 鞁犾毄 頃滊弰毳� 頇曤炒頄堨姷雼堧嫟.
韺岇澊頂勲澕鞚胳棎電� EGFR 鞏奠牅鞝� 甏�霠� 氚滌鞚� 響滌爜鞙茧 頃橂姅 ATR-04臧� 韽暔霅橃柎 鞛堨溂氅�, 鞚措姅 氙戈淡鞐愳劀 鞐瓣皠 鞎� 150,000氇�鞚� 頇橃瀽鞐愱矊 鞓來枼鞚� 氙胳供雼堧嫟. 頄ロ泟 欤检殧 毵堨澕鞀ろ啢鞙茧電� ATR-04鞚� Phase 1/2 鞁滍棙鞐愳劀 2025雲� 3攵勱赴 觳� 頇橃瀽 韴暯瓿� ATR-12鞚� Phase 1b 韱彪澕鞚� 雿办澊韯瓣皜 2026雲� 1攵勱赴鞐� 氚滍憸霅橂姅 瓴冹澊 鞛堨姷雼堧嫟. 鞛 鞁れ爜鞚� R&D 牍勳毄 $1.4 million, G&A 牍勳毄 $1.5 million, 靾滌啇鞁� $2.9 million, 順勱笀 鞛旍暋 $1.0 million鞚� 旮半頄堨姷雼堧嫟.
Azitra (NYSE American: AZTR), soci茅t茅 biopharmaceutique en phase clinique, a publi茅 ses r茅sultats financiers du T2 2025 et des mises 脿 jour op茅rationnelles. La soci茅t茅 a atteint 50% d'enr么lement dans l'essai de phase 1b d'ATR鈥�12 pour le syndrome de Netherton, affichant des donn茅es de s茅curit茅 prometteuses chez les cinq premiers patients. En outre, Azitra a obtenu une ligne de cr茅dit en actions de $20 million aupr猫s d'Alumni Capital LP.
Le portefeuille comprend ATR鈥�04, visant l'茅ruption cutan茅e associ茅e aux inhibiteurs d'EGFR, qui toucherait environ 150,000 patients aux 脡tats鈥慤nis chaque ann茅e. Les jalons 脿 venir incluent l'administration au premier patient de l'essai de phase 1/2 d'ATR鈥�04 au T3 2025 et les donn茅es topline de la phase 1b d'ATR鈥�12 au T1 2026. Les r茅sultats financiers indiquent des d茅penses R&D de $1.4 million, des d茅penses G&A de $1.5 million et une perte nette de $2.9 million, avec une tr茅sorerie de $1.0 million.
Azitra (NYSE American: AZTR), ein biopharmazeutisches Unternehmen in der klinischen Phase, berichtete 眉ber die Finanzergebnisse und Unternehmensupdates f眉r Q2 2025. Das Unternehmen erreichte 50% Einschreibung in der Phase鈥�1b鈥慡tudie von ATR鈥�12 f眉r das Netherton鈥慡yndrom und zeigte vielversprechende Sicherheitsdaten bei den ersten f眉nf Patienten. Zus盲tzlich sicherte sich Azitra eine $20 million Eigenkapitallinie von Alumni Capital LP.
Die Pipeline umfasst ATR鈥�04, das auf EGFRi鈥慳ssoziierten Hautausschlag abzielt und j盲hrlich rund 150,000 US鈥慞atienten betrifft. Wichtige anstehende Meilensteine sind die Erstpatientendosierung in der Phase鈥�1/2鈥慡tudie von ATR鈥�04 im Q3 2025 und die Topline鈥慏aten der Phase鈥�1b鈥慡tudie von ATR鈥�12 im Q1 2026. Die Finanzergebnisse zeigen F&E鈥慉ufwendungen von $1.4 million, G&A鈥慉ufwendungen von $1.5 million und einen Nettoverlust von $2.9 million, bei einer Barposition von $1.0 million.
- Secured $20 million equity line of credit for clinical pipeline funding
- Achieved 50% enrollment in Phase 1b trial of ATR-12 with promising safety profile
- Targeting large market opportunity with ATR-04 (150,000 US patients annually)
- Clear pipeline milestones set for Q3 2025 and Q1 2026
- Increased net loss to $2.9 million from $2.6 million year-over-year
- Low cash position of $1.0 million as of June 30, 2025
- Higher R&D expenses at $1.4 million compared to $1.1 million in previous year
Insights
Azitra reports promising safety data for Netherton syndrome treatment while facing significant cash constraints with $1M remaining.
Azitra's Q2 2025 results show both clinical progress and financial challenges. The company has reached 50% enrollment in its Phase 1b trial for ATR-12 in Netherton syndrome with promising initial safety results. This represents significant advancement for a disease with no approved treatments, potentially offering hope for patients with this rare chronic condition.
The company is also advancing its ATR-04 program for EGFR inhibitor-associated rash, which affects approximately 150,000 patients annually in the US. First patient dosing is expected in Q3 2025, with the trial design recently presented at ASCO.
However, Azitra's financial position is concerning. With just
The recently established equity line of credit with Alumni Capital LP (up to
Q2 2025 and Recent Business Highlights
- Announced initial safety results and
50% enrollment of the Phase 1b clinical trial of the ATR-12 program in Netherton syndrome, demonstrating a promising safety profile
- Announced acceptance of poster detailing the Phase 1/2 clinical trial of the ATR-04 program in EGFR inhibitor ("EGFRi")-associated rash at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
- Entered into a purchase agreement for up to
$20 million
"The first half of 2025 was a vital period for Azitra as we hit a key milestone in our first-in-class, precision, live biotherapeutic candidates designed for major undertreated dermatological diseases," said Francisco Salva, CEO of Azitra. "For ATR-12, our lead program targeting the rare, chronic and devastating Netherton syndrome, we announced promising safety data in the first five patients dosed with ATR12-351, and we believe this novel approach has potential to be life-changing for these patients. Netherton syndrome has a high unmet need with no approved treatment options."
Mr. Salva continued: "We also announced the design of our Phase 1/2 trial with our ATR-04 program at ASCO, which is investigating a live biotherapeutic product candidate containing an isolated, naturally derived S. epidermidis strain being developed for the treatment of EGFRi-associated rash. EGFRi-associated rash is a dermatologic toxicity that often accompanies EGFRi treatments for cancer, impacting approximately 150,000 patients in
Mr. Salva concluded: "The remainder of 2025 is anticipated to be a milestone-rich period for Azitra during which we look forward to showcasing the potential of ATR-12 and ATR-04, as well as our unique, proprietary platform for delivering engineered proteins using topical live biotherapeutic products."
Pipeline and Anticipated Milestones
- Q3 2025: First patient to be dosed with for EGFRi-associated rash in a Phase 1/2 trial for ATR-04
- Q1 2026: Topline data of the Phase 1b trial with ATR-12 in Netherton syndrome patients
Financial Results for the Quarter Ended June 30, 2025
- Research and Development (R&D) expenses: R&D expenses for the quarter ended June 30, 2025, were
$1.4 million $1.1 million - General and Administrative (G&A) expenses: G&A expenses for the quarter ended June 30, 2025, were
$1.5 million $1.5 million - Net Loss was
$2.9 million $2.6 million - Cash and cash equivalents: As of June 30, 2025, Azitra had cash and cash equivalents of
$1.0 million
About Azitra, Inc.
Azitra, Inc. is a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology. Azitra's lead program, ATR-12, uses an engineered strain of S. epidermidis designed to treat Netherton syndrome, a rare, chronic skin disease with no approved treatment options. Netherton syndrome may be fatal in infancy with those living beyond a year having profound lifelong challenges. The ATR-12 program includes a Phase 1b clinical trial in adults with Netherton syndrome. ATR-04, Azitra's additional clinical program, utilizes another engineered strain of S. epidermidis for the treatment of EGFR inhibitor ("EGFRi") associated skin toxicity; a Phase 1/2 clinical trial has been initiated for this program. Azitra has received Fast Track designation from the United States Food and Drug Administration for this program to treat EGFRi associated rash, which impacts approximately 150,000 people in
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will," and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, statements regarding the expected timing of (i) our provision of initial safety data and topline results for the phase 1b trial for our ATR-12, (ii) the abstract detailing the Phase 1/2 clinical trial for our ATR-04 program, (iii) the initiation of dosing in the Phase 1/2 clinical trial for our ATR-04 program, and (iv) statements about our clinical and preclinical programs, and corporate and clinical/preclinical strategies.
Any forward-looking statements in this press release are based on current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to that we may experience delays in the provision of initial safety data and topline results for ATR-12 or, if we do, that such data may not be favorably received, we may fail to present this abstract detailing the Phase 1/2 clinical trial or, if we are able to do so, that the abstract will be favorably received; we may experience delays in the dosing the first patient in this Phase 1/2 trial; our product candidates may not be effective; there may be delays in regulatory approval or changes in regulatory framework that are out of our control; our estimation of addressable markets of our product candidates may be inaccurate; we may fail to timely raise additional required funding; more efficient competitors or more effective competing treatment may emerge; we may be involved in disputes surrounding the use of our intellectual property crucial to our success; we may not be able to attract and retain key employees and qualified personnel; earlier study results may not be predictive of later stage study outcomes; and we are dependent on third-parties for some or all aspects of our product manufacturing, research and preclinical and clinical testing. Additional risks concerning Azitra's programs and operations are described or incorporated by reference in our annual report on Form 10-K filed with the United States Securities and Exchange Commission on February 24, 2025. Azitra explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.
Contact
Norman Staskey
Chief Financial Officer
[email protected]
Investor Relations
Tiberend Strategic Advisors, Inc.
Jon Nugent
205-566-3026
[email protected]
Media Relations
Tiberend Strategic Advisors, Inc.
Casey McDonald
646-577-8520
[email protected]
Condensed Statement of Operations (Unaudited) | ||||||||
Three months Ended June 30, | ||||||||
2025 | 2024 | |||||||
Service revenue 鈥� related party | $ | - | $ | 7,500 | ||||
Total revenue | - | 7,500 | ||||||
Operating expenses: | ||||||||
General and administrative | 1,469,513 | 1,549,228 | ||||||
Research and development | 1,401,839 | 1,118,552 | ||||||
Total operating expenses | 2,871,352 | 2,667,780 | ||||||
Loss from operations | (2,871,352) | (2,660,280) | ||||||
Other income (expense): | ||||||||
Interest income | 15,461 | 16,268 | ||||||
Interest expense | (468) | (1,782) | ||||||
Change in fair value of warrants | 54 | 4,272 | ||||||
Other expense | (32,688) | 9,529 | ||||||
Total other income (expense) | (17,641) | 28,287 | ||||||
Net loss before income taxes | (2,888,993) | (2,631,993) | ||||||
Income tax expense | - | - | ||||||
Net loss | $ | (2,888,993) | $ | (2,631,993) | ||||
Net loss attributable to common shareholders | $ | (2,888,993) | (2,631,993) | |||||
Net loss per Share, basic and diluted | $ | (0.18) | $ | (2.74) | ||||
Weighted average common stock outstanding, basic and diluted | 16,279,574 | 960,146 | ||||||
听
Condensed Balance Sheets (Unaudited) | ||||||||
June 30, | December 31, | |||||||
2025 | 2024 | |||||||
Assets | ||||||||
Current Assets: | ||||||||
Cash and cash equivalents | $ | 1,045,730 | $ | 4,554,719 | ||||
Other receivables | 78,407 | 101,896 | ||||||
Prepaid expenses and other current assets | 675,553 | 571,675 | ||||||
Total current assets | $ | 1,799,690 | $ | 5,228,290 | ||||
听Property and equipment, net | 601,504 | 653,957 | ||||||
Other assets | 1,554,828 | 1,476,555 | ||||||
Total assets | $ | 3,956,022 | $ | 7,358,802 | ||||
听Liabilities, and stockholders' equity | ||||||||
Current liabilities: | ||||||||
Accounts payable | $ | 635,842 | $ | 490,255 | ||||
Current financing lease liability | 16,854 | 16,066 | ||||||
Current operating lease liability | 286,499 | 255,177 | ||||||
Accrued expenses | 513,166 | 614,359 | ||||||
Total current liabilities | 1,452,361 | 1,375,857 | ||||||
Long-term financing lease liability | 1,479 | 10,105 | ||||||
Long-term operating lease liability | 273,027 | 274,161 | ||||||
Warrant liability | 184 | 381 | ||||||
Total liabilities | 1,727,051 | 1,660,504 | ||||||
Stockholders' equity | ||||||||
Common stock | 1,798 | 763 | ||||||
Additional paid-in capital | 65,750,337 | 63,263,360 | ||||||
Accumulated deficit | (63,523,164) | (57,565,825) | ||||||
Total stockholders' equity | 2,228,971 | 5,698,298 | ||||||
Total liabilities and stockholders' equity | $ | 3,956,022 | $ | 7,358,802 | ||||
听
View original content to download multimedia:
SOURCE Azitra, Inc.
FAQ
What were Azitra's (AZTR) key financial results for Q2 2025?
What is the status of Azitra's ATR-12 clinical trial for Netherton syndrome?
How much funding did Azitra (AZTR) secure in Q2 2025?
What is the market potential for Azitra's ATR-04 treatment?
What are Azitra's (AZTR) upcoming milestones for 2025-2026?
